References
- Berg M, Childs R. Ex vivo expansion of NK cells: what is the priority – high yield or high purity? Cytotherapy. 2010;12: 969–70.
- Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G, . Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy. 2010; 12:1044–55.
- Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, . Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111:3155–62.
- Prevost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J Immunol. 1998; 161:2187–94.
- Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol. 2005;17:195–201.
- Speiser DE, Romero P. Toward improved immunocompetence of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1467–9.
- Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115:1616–26.
- Matter M, Pavelic V, Pinschewer DD, Mumprecht S, Eschli B, Giroglou T, . Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res. 2007;67:7467–76.
- Carlens S, Liu D, Ringden O, Aschan J, Christensson B, Levitsky V, . Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion. J Hematother Stem Cell Res. 2002;11:669–74.
- Wolf H, Muller Y, Salmen S, Wilmanns W, Jung G. Induction of anergy in resting human T lymphocytes by immobilized anti-CD3 antibodies. Eur J Immunol. 1994;24:1410–7.
- Mesel-Lemoine M, Cherai M, Le Gouvello S, Guillot M, Leclercq V, Klatzmann D, . Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy. Blood. 2006; 107:381–8.
- Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, . Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy. 2009;1:753–64.
- Alici E, Konstantinidis KV, Sutlu T, Aints A, Gahrton G, Ljunggren HG, . Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp Hematol. 2007;35:1839–46.
- Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, . Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11:341–55.
- Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy. 2004; 6:15–22.
- Huenecke S, Zimmermann SY, Kloess S, Esser R, Brinkmann A, Tramsen L, . IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16− subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother. 2010;33:200–10.